NEW YORK (GenomeWeb) – Danaher today reported that revenues in its second quarter grew almost 4 percent year over year with growth in its Life Sciences and Diagnostics segment a little less than 3 percent. 

For the three months ended July 3, the Washington-based conglomerate posted total revenues of $5.13 billion, up from $4.96 billion in the year-ago quarter, and above the consensus Wall Street estimate of $5.06 billion. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.